Madera TR Compounds: Optimized ClpP Activators
Madera has developed a new generation of highly potent, specific small-molecule activators of the mitochondrial protease ClpP. ClpP is the proteolytic core of the mitochondrial ClpXP complex and plays a central role in mitochondrial protein quality control. By directly activating ClpP, Madera’s compounds disrupt mitochondrial proteostasis and metabolic function, selectively impairing cancer-cell survival mechanisms used by difficult-to-treat tumors.
A seminal discovery defining the ClpP agonist field came from Professor Lee M. Graves at UNC-Chapel Hill and Madera, who identified the mitochondrial protease ClpP as the primary biological target responsible for the anticancer activity of ONC201 and related TR compounds. This finding established ClpP activation as the central mechanism underlying this new class of mitochondrial anticancer agents and provided the biological foundation for understanding how these drugs can be developed and used therapeutically. The importance of this discovery was subsequently independently validated by Michael Andreeff, MD, and colleagues at MD Anderson, who showed that imipridone activation of ClpP induces selective cancer-cell lethality through mitochondrial proteolysis.
The TR compounds are Madera’s proprietary, highly optimized ClpP activators, discovered and advanced by Madera and extensively characterized by leading academic and government research investigators. Lead agents, including TR-57, TR-65, and TR-107, are orally bioavailable small molecules designed for high ClpP specificity, strong cell permeability, and properties compatible with oral drug development.
Compared with first-generation ClpP agonists such as dordaviprone/ONC201, Madera’s TR compounds demonstrate substantially greater potency and are designed to enable stronger and more effective target modulation in cancer tissue.
ONC201 Validates the Mechanism — But Was Only the Starting Point
The clinical activity and approval of dordaviprone/ONC201 provide important validation for ClpP activation as an anticancer mechanism. ONC201 was a first-generation, screening-derived molecule, not an agent originally optimized for ClpP activation. Its clinical benefit therefore suggests that the underlying biology is important — and that more potent, purpose-built ClpP activators may expand the therapeutic potential of this mechanism.
Modeyso™ received accelerated FDA approval for adult and pediatric patients 1 year of age and older with progressive H3 K27M-mutant diffuse midline glioma. In the integrated efficacy population, dordaviprone produced a 22% overall response rate, with a median duration of response of 10.3 months.
This is central to Madera’s opportunity: if a first-generation screening-derived compound can become a useful anticancer drug, then optimized next-generation ClpP activators may deliver more effective target modulation and broader clinical utility.
ONC201 Tolerability: Key Differentiation from Complex I Inhibitors
ONC201 also provides an important tolerability signal for ClpP activation. This matters because mitochondrial oncology is often viewed through the clinical experience of direct Complex I inhibitors, a class that has faced narrow therapeutic margins.
Three clinical-stage Complex I inhibitors illustrate the issue: BAY 87-2243 from Bayer entered Phase I development but was terminated because of drug-related adverse events; IACS-010759 from MD Anderson/IACS was limited by a narrow therapeutic index, including elevated blood lactate and neurotoxicity; and ASP4132 from Astellas encountered dose-limiting toxicities including fatigue, mental-status changes, dizziness, lactic acidosis, enteritis, and posterior reversible encephalopathy syndrome.
Together, these agents created a class concern around direct Complex I inhibition: metabolic toxicity, lactate liability, neurologic adverse events, and difficulty sustaining active exposure.
ClpP activation is different. Rather than directly blocking electron transport, ClpP agonists activate a mitochondrial protease and disrupt mitochondrial proteostasis. The clinical tolerability of ONC201 — including pediatric diffuse midline glioma/DIPG experience and high-risk post-transplant AML/MDS maintenance — supports ClpP activation as a distinct mitochondrial strategy, not another variant of Complex I inhibition.
In a pediatric Phase I study in H3 K27M-mutant diffuse midline glioma and DIPG, weekly ONC201 dosing scaled from the adult 625 mg dose was reported to be well tolerated. In a recent Phase I study of dordaviprone maintenance after allogeneic HCT in high-risk AML and MDS, weekly oral dosing produced no dose-limiting toxicities or graft failures, no discontinuations due to adverse events, and relatively low Grade 3–4 cytopenias in a fragile post-transplant population.
Targeting Resistance, Relapse, and Cancer Stem-Like Cells
A key feature of ClpP activation is its potential impact on tumor cell populations associated with relapse, metastasis, and therapeutic resistance. Published work from Stanley Lipkowitz and colleagues at NIH/NCI, together with UNC and Madera, showed that ClpP agonists inhibit breast cancer stem-cell function by disrupting mitochondrial homeostasis. In these studies, ClpP agonists impaired mammosphere formation, reduced stem-like cell markers, and inhibited tumor-initiation capacity in vivo.
Mechanistically, ClpP activation affects multiple pathways required for cancer stem-cell function, including oxidative phosphorylation, redox balance, NAD/NADPH metabolism, YAP, Myc, HIF signaling, one-carbon metabolism, and proline biosynthesis. This multi-pathway disruption distinguishes ClpP activation from therapies focused on a single signaling node.
Independent Scientific Validation
Research teams at UNC, NIH/NCI, the University of Toronto, Flinders University, Stony Brook University, the University of Sydney, and Duke University have characterized the biological and structural effects of the TR compounds, including cancer growth inhibition, disruption of mitochondrial metabolism, effects on cancer stem-like cell function, and direct interactions with ClpP.
Together, these findings support ClpP agonism as a unique mechanism in cancer drug therapy: clinically validated by ONC201, advanced by Madera’s optimized TR compounds, broadly orthogonal to other cancer-treatment modalities, and supported by compelling tolerability that creates opportunities to leverage this mechanism in combination regimens as well as in single-agent treatment.
